AUTHORS
Bradley Hunter, MD, MPH, Jacob Wilkes, BS2, Carter Larsen3, Jesse Gygi, MHA, MPH4
AFFILIATIONS
1 Intermountain Health, Salt Lake City, Utah, United States
2 Intermountain Health, Salt Lake City, Utah, United States
3 Brigham Young University, Provo, Utah, United States
4 Intermountain Health, Salt Lake City, Utah, United States
ABSTRACT
Introduction
Autologous stem cell transplantation and Chimeric Antigen Receptor T-cell (CART) therapy both begin with apheresis-based collection of the patient’s own cells. Collection closer to the patient’s home may reduce travel burden and increase incidence of collection. In February 2025, Intermountain Health (IH) became the first program in the United States to collect CART products at a satellite site, roughly 300 miles and a 4.5-hour drive away from the main treatment center. The FDA’s subsequent removal of REMS site certification makes this model widely available, raising the question of whether decentralized collection can reduce patient travel burden while preserving collection quality and safety.
Methods
Adults (≥18 years) undergoing apheresis for autologous peripheral blood stem cell (PBSC) or CART collection within IH from Jan 1, 2024 – Jun 30, 2026 were identified. Satellite collection at St. George Regional Hospital, with cryopreservation and shipment to LDS Hospital in Salt Lake City, began Feb 10, 2025; patients collected at LDS Hospital over the same period served as the comparator. Straight-line distance was calculated from the patient’s residence to represent travel burden, with avoided overnight stays estimated separately for PBSC and CART collection. Patient addresses determined Area Deprivation Index Scores and Rural Urban Commuting Area. Collection adequacy comprised CD34+ yield, number of collection days, failed collection for PBSC, and incidence of PBMC leukapheresis for CART. Safety comprised hospitalization and mortality within 30 days of collection.
Results
Between Feb 10, 2025 and Jun 30, 2026, 24 collections for 22 patients were performed at the satellite site: 11 PBSC and 13 CAR T. Mean age was 64.4 years (SD 14.7), 63.6% were male, and median Charlson comorbidity index was 5 (IQR 4–8.75). Lymphoma was the most common indication (59.1%), followed by multiple myeloma (36.4%). Utah residents accounted for 54.5% of satellite collections, and notably, 40.9% of all satellite patients traveled from the Las Vegas area, compared with 3.6% of the 84 patients collected centrally over the same period. Satellite patients more often lived in top-quintile deprivation neighborhoods (27.3% vs 9.5%), were non-White (22.7% vs 6.0%) or Hispanic (13.6% vs 7.1%), and preferred a language other than English (13.6% vs 6.0%).
Satellite patients lived a median of 271.2 miles (IQR 265.8–363.7) from the transplant center but only 35.1 miles (IQR 5.7–108.8) from the satellite site, saving a median of 254.8 miles (IQR 250.0–263.0) of one-way travel. This saved 12,045 miles of travel, or 548 miles per patient. Thirteen patients (59%) avoided overnight stays, saving an estimated 72 hotel nights (2 nights per CART and 7.5 nights per PBSC). All satellite patients lived at least 100 miles closer to the satellite site than to the transplant center, as did a further 15.5% of patients collected centrally.
All 11 satellite PBSC collections succeeded, with a mean CD34+ yield of 8.2 × 106 cells/kg (SD 4.3) obtained over a mean of 2.5 collection days (SD 0.5); yields were at least as high as those collected centrally in the same period (5.6, SD 2.2) or in the central pre-period (7.5, SD 4.1). 10 of 11 satellite collections (90.9%) proceeded to transplant, consistent with the central pre-period rate of 92.5%.
30-day outcomes after infusion for the satellite collection patients were similar to concurrent central collection. For PBSC patients, there were no re-hospitalizations in the 30 days after infusion. , CRS events occurred in 5 satellite patients (62.5%) versus 24 central patients (63.2%), and ICANS events occurred in 2 satellite patients (25%) versus 10 central patients (26.3%). No deaths occurred in the 90 days post infusion for both PBSC and CART satellite patients.
Conclusion
Among the first 22 apheresis collection patients at a satellite site, both autologous stem cell and CART collections succeeded, with CD34+ yields and 30-day outcomes comparable to concurrent central collection. Satellite collection saved a median of 254.8 miles of one-way travel per patient and an estimated 72 hotel nights across the cohort, with the greatest benefit among patients travelling from southern Utah. Decentralized collection is a safe and scalable route to reduce the travel burden of cellular therapy.
DISCLOSURES
Bradley Hunter, MD, MPH: Caribou Biosciences - Honoraria; Poseida Therapeutics - Honoraria; Kite - Honoraria; BMS - Honoraria; Kyverna (paid to institution) - Honoraria; Johnson & Johnson - Honoraria; Novartis - Honoraria; Johnson & Johnson - Research Funding; BMS - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Kyverna - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony); Poseida Therapeutics - Consultancy (Includes expert testimony)